PL2384327T3 - Związki ze skondensowanym pierścieniem i ich zastosowanie - Google Patents

Związki ze skondensowanym pierścieniem i ich zastosowanie

Info

Publication number: PL2384327T3
Authority: PL; Poland
Prior art keywords: fused ring; ring compound; compound; fused; ring
Prior art date: 2009-01-30

Application number

PL10703532T

Other languages

English (en)

Inventor

Tsuyoshi Maekawa

Hideyuki Igawa

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-30

Filing date

2010-01-29

Publication date

2013-12-31

2010-01-29 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2013-12-31 Publication of PL2384327T3 publication Critical patent/PL2384327T3/pl

Links

150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL10703532T 2009-01-30 2010-01-29 Związki ze skondensowanym pierścieniem i ich zastosowanie PL2384327T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2009020720		2009-01-30
PCT/JP2010/051651 WO2010087515A1 (en)	2009-01-30	2010-01-29	Fused ring compound and use thereof
EP10703532.1A EP2384327B1 (en)	2009-01-30	2010-01-29	Fused ring compound and use thereof

Publications (1)

Publication Number	Publication Date
PL2384327T3 true PL2384327T3 (pl)	2013-12-31

Family

ID=42026435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10703532T PL2384327T3 (pl)	2009-01-30	2010-01-29	Związki ze skondensowanym pierścieniem i ich zastosowanie

Country Status (36)

Country	Link
US (4)	US8283353B2 (pl)
EP (1)	EP2384327B1 (pl)
JP (2)	JP4892649B1 (pl)
KR (1)	KR20110113758A (pl)
CN (2)	CN102369205B (pl)
AR (1)	AR075344A1 (pl)
AU (1)	AU2010208863A1 (pl)
CA (1)	CA2750710C (pl)
CL (1)	CL2011001848A1 (pl)
CO (1)	CO6362011A2 (pl)
CR (1)	CR20110463A (pl)
CY (1)	CY1114530T1 (pl)
DK (1)	DK2384327T3 (pl)
DO (1)	DOP2011000249A (pl)
EA (1)	EA019823B1 (pl)
EC (1)	ECSP11011294A (pl)
ES (1)	ES2433225T3 (pl)
GE (1)	GEP20135961B (pl)
HR (1)	HRP20131017T1 (pl)
IL (1)	IL214283A0 (pl)
MA (1)	MA33071B1 (pl)
ME (1)	ME01621B (pl)
MX (1)	MX2011008058A (pl)
MY (1)	MY152946A (pl)
NZ (1)	NZ594606A (pl)
PE (1)	PE20120593A1 (pl)
PL (1)	PL2384327T3 (pl)
PT (1)	PT2384327E (pl)
RS (1)	RS53012B (pl)
SG (1)	SG173135A1 (pl)
SI (1)	SI2384327T1 (pl)
TN (1)	TN2011000368A1 (pl)
TW (2)	TWI468410B (pl)
UY (1)	UY32409A (pl)
WO (1)	WO2010087515A1 (pl)
ZA (1)	ZA201105867B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2750710C (en)	2009-01-30	2018-09-04	Takeda Pharmaceutical Company Limited	Fused ring compound and use thereof
SI2655375T1 (sl)	2010-12-23	2015-03-31	Sanofi	Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
CZ304252B6 (cs) *	2011-04-11	2014-01-29	Zentiva, K. S.	Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
MX388824B (es)	2016-06-20	2025-03-20	Novartis Ag	Formas cristalinas de compuesto de triazolopirimidina.
KR102437623B1 (ko)	2017-09-26	2022-08-26	에코랍 유에스에이 인코퍼레이티드	산/음이온성 항균 및 살바이러스 조성물 및 이의 용도
SG11202011881PA (en)	2018-05-31	2020-12-30	Hua Medicine Shanghai Ltd	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
MX2022001940A (es)	2019-08-14	2022-05-10	Incyte Corp	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN115298177B (zh)	2019-10-11	2025-01-17	因赛特公司	作为cdk2抑制剂的双环胺
CN112745319B (zh) *	2019-10-30	2022-06-17	中国科学院上海药物研究所	一类取代三环结构的化合物、其制备方法及用途
EP4075976A1 (en)	2019-12-16	2022-10-26	Ecolab USA Inc.	Anionic surfactant impact on virucidal efficacy
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5472967A (en)	1991-02-20	1995-12-05	Synthelabo	4-pyrimidinone derivatives their preparation and their application in therapy
FR2672892B1 (fr) *	1991-02-20	1994-01-14	Synthelabo	Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
IL102183A (en) *	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
TW251288B (pl) *	1991-06-27	1995-07-11	Takeda Dharm Industry Co Ltd
IT1250749B (it)	1991-08-02	1995-04-21	Luso Farmaco Inst	Composti eterociclici ad attivita' a ii antagonista
FR2687677B1 (fr) *	1992-02-24	1996-10-11	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5389632A (en) *	1992-02-24	1995-02-14	Laboratoires Upsa	Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5387747A (en) *	1992-02-24	1995-02-07	Laboratoires Upsa	Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
IT1263804B (it)	1993-01-22	1996-09-03	Luso Farmaco Inst	Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en)	1994-03-31	1994-05-25	Merck Sharp & Dohme	Medicaments
KR19990022723A (ko)	1995-06-07	1999-03-25	윌리암스 로저 에이	울혈성심부전의 치료를 위한 스피로노락톤 및 앤지오텐신 ii 길 항제 복합요법
WO1996040255A2 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
WO1996040256A1 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
CN1522701A (zh)	1995-06-07	2004-08-25	G.D.ɪ��˾	环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
FR2812876B1 (fr)	2000-08-08	2002-09-27	Galderma Res & Dev	Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv)	2001-05-04	2001-05-04	Astrazeneca Ab	New compounds
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en)	2003-01-24	2004-10-01	Tanabe Seiyaku Co	A pyrazolopyrimidine compound and a process for preparing the same
WO2005020984A2 (en)	2003-08-29	2005-03-10	Aaipharma Inc.	Method of reducing the risk of oxidative stress
WO2005074603A2 (en) *	2004-02-03	2005-08-18	Abbott Laboratories	Aminobenzoxazoles as therapeutic agents
BRPI0511768A (pt)	2004-06-02	2008-01-08	Takeda Pharmaceutical	composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto
US20050288272A1 (en) *	2004-06-23	2005-12-29	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
RU2384346C2 (ru)	2004-06-23	2010-03-20	Зольвай Фармасьютиклз Гмбх	Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
JP5140587B2 (ja)	2005-07-27	2013-02-06	モルリサーチアプリケーションズリミテッド	腎臓、血管および軟骨の病理を治療におけるレニン−アンギオテンシン系の阻害
WO2007051007A2 (en)	2005-10-28	2007-05-03	Novartis Ag	Combination of antihypertensives with cholesterol-lowering agent
WO2007053406A1 (en)	2005-10-28	2007-05-10	Novartis Ag	Combinations of antihypertensive and cholesterol lowering agents
US20080064871A1 (en)	2006-05-26	2008-03-13	Japan Tobacco Inc.	Production Method of Nitrogen-Containing Fused Ring Compounds
US20080132474A1 (en)	2006-11-09	2008-06-05	Gene Logic Inc.	Breast cancer screening and treatment methods
US20090012052A1 (en)	2006-11-09	2009-01-08	Ore Pharmaceuticals Inc.	Method for treating er+ breast cancer
US20080207654A1 (en) *	2006-11-24	2008-08-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound and use thereof
EP2253630A1 (en) *	2007-05-21	2010-11-24	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
US20100221340A1 (en)	2007-09-20	2010-09-02	University Of Rochester	Method and compositions for treatment or prevention of inflammatory conditions
EP2268612B1 (en)	2008-03-24	2014-08-20	Novartis AG	Arylsulfonamide-based matrix metalloprotease inhibitors
EP2279009A4 (en)	2008-05-05	2011-09-21	Univ Rochester	METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
CA2750710C (en)	2009-01-30	2018-09-04	Takeda Pharmaceutical Company Limited	Fused ring compound and use thereof

2010
- 2010-01-29 CA CA2750710A patent/CA2750710C/en not_active Expired - Fee Related
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Withdrawn
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/en not_active Ceased
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/en active Active
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 HR HRP20131017AT patent/HRP20131017T1/hr unknown
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 RS RS20130472A patent/RS53012B/sr unknown
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown

Also Published As

Publication number	Publication date
CA2750710C (en)	2018-09-04
US20100197683A1 (en)	2010-08-05
US20110294832A1 (en)	2011-12-01
JP2011251970A (ja)	2011-12-15
US20140046056A1 (en)	2014-02-13
DK2384327T3 (da)	2013-10-28
DOP2011000249A (es)	2011-09-15
MX2011008058A (es)	2011-09-01
TN2011000368A1 (en)	2013-03-27
EA019823B1 (ru)	2014-06-30
AR075344A1 (es)	2011-03-23
EP2384327A1 (en)	2011-11-09
EP2384327B1 (en)	2013-07-31
CO6362011A2 (es)	2012-01-20
TW201031669A (en)	2010-09-01
US20110288087A1 (en)	2011-11-24
GEP20135961B (en)	2013-11-11
CN102369205A (zh)	2012-03-07
ZA201105867B (en)	2012-10-31
ES2433225T3 (es)	2013-12-10
TW201444848A (zh)	2014-12-01
SG173135A1 (en)	2011-08-29
MA33071B1 (fr)	2012-02-01
ME01621B (me)	2014-09-20
RS53012B (sr)	2014-04-30
CY1114530T1 (el)	2017-01-25
EA201101138A1 (ru)	2012-04-30
CL2011001848A1 (es)	2012-02-03
SI2384327T1 (sl)	2013-12-31
CA2750710A1 (en)	2010-08-05
KR20110113758A (ko)	2011-10-18
WO2010087515A1 (en)	2010-08-05
HK1162505A1 (en)	2012-08-31
JP2012513952A (ja)	2012-06-21
JP5676379B2 (ja)	2015-02-25
NZ594606A (en)	2013-06-28
US8921379B2 (en)	2014-12-30
PE20120593A1 (es)	2012-05-21
MY152946A (en)	2014-12-15
CN103788097B (zh)	2016-03-30
HRP20131017T1 (hr)	2013-12-06
US8592431B2 (en)	2013-11-26
US8283353B2 (en)	2012-10-09
JP4892649B1 (ja)	2012-03-07
CN102369205B (zh)	2014-10-29
TWI468410B (zh)	2015-01-11
PT2384327E (pt)	2013-11-07
US9115136B2 (en)	2015-08-25
CR20110463A (es)	2011-12-01
ECSP11011294A (es)	2011-09-30
CN103788097A (zh)	2014-05-14
UY32409A (es)	2010-08-31
AU2010208863A1 (en)	2011-09-08
IL214283A0 (en)	2011-09-27

Publication	Publication Date	Title
IL214283A0 (en)	2011-09-27	Fused ring compound and use thereof
EP2586325A4 (en)	2014-03-12	RING WITH ADJUSTABLE INTERNAL DIAMETER
HUE059796T2 (hu)	2022-12-28	PSMA-t célzó vegyületek és alkalmazásaik
AU328140S (en)	2009-10-26	Ring
ZA201007682B (en)	2011-12-28	Fused ring compounds and use thereof
GB2473880B (en)	2015-04-01	Split ring component
ZA201204670B (en)	2013-03-27	Seven-membered ring compound and pharmaceutical use therefor
GB0902173D0 (en)	2009-03-25	Compounds and their use
GB201101808D0 (en)	2011-03-16	Ring bearer cane
GB2474682B (en)	2013-08-07	Ring binder
GB0922510D0 (en)	2010-02-10	Compound and use
GB0922259D0 (en)	2010-02-03	Constriction ring
SI2246181T1 (sl)	2013-01-31	Kompozitni material in njegova uporaba
ZA201201795B (en)	2013-05-29	Fused heterocyclic ring derivative and use thereof
GB0817414D0 (en)	2008-10-29	Sutassist-suture ring
GB0920850D0 (en)	2010-01-13	Ring
AU328902S (en)	2009-12-15	Ring
GB0902013D0 (en)	2009-03-11	Novel compounds and their use
PL118886U1 (pl)	2011-10-10	Obrączka
GB0905231D0 (en)	2009-05-13	Compounds and their use
AU328903S (en)	2009-12-15	Pendant
AU328905S (en)	2009-12-15	Pendant
AU328904S (en)	2009-12-15	Pendant
TWM370037U (en)	2009-12-01	Filtering connection ring
GB0910870D0 (en)	2009-08-05	Penis enlargement ring